Operator
Good morning, and welcome to the Shattuck Labs Investor Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I will now turn the call over to Shattuck’s Chief Financial Officer, Mr. Andrew Neill. Please go ahead.
Andrew Neill
Chief Financial Officer
Thank you, operator. Good morning, everyone, and thank you for joining. During today’s call, we will be providing a company update, including clinical data from the Phase I clinical trial of our potentially first-in-class DR3 blocking antibody, SL-325. The press release reporting our company update was issued premarket this morning and can be found on the Investor Relations section of our website, shattucklabs.com.
Before we begin, I would like to remind you that today’s webcast contains forward-looking statements and would refer you to our most recent 10-Q, our most recently filed corporate presentation and our other filings with the SEC, which are available from the SEC’s website or on our corporate website, shattucklabs.com. I am joined on today’s webcast by Dr. Taylor Schreiber, our Co-Founder and Chief Executive Officer; Dr. Lini Pandite, our Chief Medical Officer; Dr. Suresh de Silva, our Chief Scientific Officer; and Dr. Michael Choi, our VP of Clinical Development. We will start with results from the Phase I trial of SL-325 in healthy volunteers, including
